Levi & Korsinsky announces it has commenced an investigation of Alkermes plc (NASDAQGS: ALKS) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On January 21, 2016, Alkermes announced that its depression treatment ALKS 5461 did not meet the primary efficacy endpoints in two Phase 3 trials. Following this news, shares of Alkermes were down 41.90% on intraday trading on January 21, 2016. To obtain additional information, go to:
http://zlkdocs.com/ALKS-Info-Request-Form-3884
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160121006222/en/
Contacts:
Eduard Korsinsky, Esq.
Tel:
212-363-7500
Toll Free: 877-363-5972
Fax: 866-367-6510
www.zlk.com